e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

e13a2 and e14a2 are the most frequent transcript types of the fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) in order to discontinue TKI treatment and remain in the so-called treatment-free r...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical medicine Vol. 13; no. 3; p. 779
Main Authors:	Marcé, Sílvia, Méndez, Aleix, Xicoy, Blanca, Estrada, Natalia, Cabezón, Marta, Sturla, Antonella Luciana, García, Miriam Ratia, Angona, Anna, Amat, Paula, Escribano Serrat, Silvia, Scalzulli, Emilia, Morgades, Mireia, Senín, Alicia, Hernández-Boluda, Juan Carlos, Ferrer-Marín, Francisca, Anguita, Eduardo, Cortés, Montserrat, Plensa, Esther, Breccia, Massimo, García-Gutierrez, Valentín, Zamora, Lurdes
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 29-01-2024
Subjects:	Chronic myeloid leukemia Drug therapy Gene expression Gene fusion Genetic aspects Kinases Leukemia Leukemia research Patient outcomes Patients Polymerase chain reaction Regression (Disease) Remission (Medicine) Spain United States > US tyrosine kinase inhibitors chronic myeloid leukemia treatment free remission BCR::ABL1 transcript type discontinuation
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	e13a2 and e14a2 are the most frequent transcript types of the fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) in order to discontinue TKI treatment and remain in the so-called treatment-free remission (TFR) phase, but biological factors associated with these goals are not well established. This study aimed to determine the effect of transcript type on TFR in patients receiving frontline treatment with imatinib (IM) or second-generation TKI (2G-TKI). Patients treated at least 119 months with IM presented less post-discontinuation relapse than those that discontinued IM before 119 months ( = 0.005). In addition, cases with the e14a2 transcript type treated at least 119 months with IM presented a better TFR ( = 0.024). On the other hand, the type of transcript did not affect the cytogenetic or molecular response in 2G-TKI treated patients; however, the use of 2G-TKI may be associated with higher and earlier DMR in patients with the e14a2 transcript.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2077-0383 2077-0383
DOI:	10.3390/jcm13030779